Literature DB >> 8292720

Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

S Valentin1, O Nordfang, C Bregengård, P Wildgoose.   

Abstract

We have previously shown that the C-terminus of TFPI is essential for its anticoagulant activity. In the present study we have assessed the role of this region in the binding of TFPI to lipoproteins. We found that full length TFPI, but not C-terminal degraded TFPI, was capable of coeluting with the plasma lipoprotein fraction on a Superose-6 column. The importance of the TFPI C-terminus in lipoprotein interactions was also assessed using a microtitre plate binding assay. We found that full-length TFPI was capable of binding to VLDL or LDL coated microtitre plates. C-terminal degraded TFPI also bound to VLDL, but with a ten-fold lower affinity than full length TFPI. Interestingly, removal of the C-terminus along with the third Kunitz-type domain resulted in a TFPI form incapable of lipoprotein binding. Since heparin shows strong binding to the C-terminus of TFPI, we also tested its effect on the binding of full length TFPI to VLDL. We found that co-incubation of TFPI with heparin inhibited this binding in a dose-dependent manner. Heparin was also capable of releasing TFPI from a preformed TFPI:VLDL complex, although this reaction required unphysiological amounts of heparin. To assess the physiological function of heparin on FL-TFPI:lipoprotein interactions we also performed gel filtration chromatography of rabbit plasma immediately following i.v. administration of FL-TFPI with and without heparin. Previous experiments indicated that heparin has a protective effect on exogenously added FL-TFPI, increasing its recovery by ten-fold.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8292720

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

1.  Oxidized low-density lipoprotein impairs the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells.

Authors:  S Horie; S Hiraishi; Y Hirata; M Kazama; J Matsuda
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

2.  Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.

Authors:  YouFu Li; Miguel Rodriquez; Frederick A Spencer; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2002-10       Impact factor: 2.300

3.  Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2.

Authors:  Makoto Motoyoshi; Masanori Sugiyama; Yutaka Atomi; Wataru Kimura; Hirokazu Nagawa
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

4.  Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Authors:  Michiel J B Kemme; Jacobus Burggraaf; Rik C Schoemaker; Cornelis Kluft; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

5.  Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).

Authors:  Michael Dockal; Rudolf Hartmann; Markus Fries; M Christella L G D Thomassen; Alexandra Heinzmann; Hartmut Ehrlich; Jan Rosing; Frank Osterkamp; Thomas Polakowski; Ulrich Reineke; Andreas Griessner; Hans Brandstetter; Friedrich Scheiflinger
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

6.  Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.

Authors:  Thomas A White; Tucker Johnson; Natalia Zarzhevsky; Cindy Tom; Sinny Delacroix; Eric W Holroyd; Susan A Maroney; Ripudamanjit Singh; Shuchong Pan; William P Fay; Jan van Deursen; Alan E Mast; Gurpreet S Sandhu; Robert D Simari
Journal:  Blood       Date:  2010-06-01       Impact factor: 22.113

Review 7.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

8.  Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix.

Authors:  Julie A Peterson; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-08       Impact factor: 10.514

9.  Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.

Authors:  Mari Tinholt; Benedicte Stavik; William Louch; Cathrine Rein Carlson; Marit Sletten; Wolfram Ruf; Grethe Skretting; Per Morten Sandset; Nina Iversen
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.